ERNESTO ZILBERBERG: Open Payments
NPI 1053346569 · NORTH ANDOVER, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$93,232 in 342 payments from 14 companies in 2025. Trend: 2023 $3,712 · 2024 $41,770 · 2025 $93,232
Speaker / faculty: $70,594Consulting: $11,190Food & beverage: $8,359Travel & lodging: $2,921Education: $168
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 66 | $46,793 |
| Alkermes, Inc. | 50 | $27,400 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 62 | $15,362 |
| Vanda Pharmaceuticals Inc. | 35 | $565 |
| Janssen Pharmaceuticals, Inc | 19 | $526 |
| Otsuka America Pharmaceutical, Inc. | 16 | $455 |
| Neurocrine BioSciences, Inc. | 13 | $401 |
| ABBVIE INC. | 18 | $384 |
| Lundbeck LLC | 16 | $368 |
| E.R. Squibb & Sons, L.L.C. | 15 | $283 |
Products named: UZEDY, LYBALVI, CAPLYTA, AUSTEDO XR, REXULTI, FANAPT, INGREZZA, VRAYLAR.
Industry payments across MA — which companies pay providers there.
